Much anticipated knockoff versions of costly biotech medicines are facing delays and obstacles that could cost patients and health systems billions in missed savings.
Biotech drugs still won't copy
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.